ReviewAmerican journal of physiology. Heart and circulatory physiology2025
Endothelial dysfunction in chronic kidney disease: a clinical perspective.
Review in American journal of physiology. Heart and circulatory physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Acute isometric handgrip exercise enhances cardiac baroreflex sensitivity and lowers systolic blood pressure in chronic kidney disease.Autonomic neuroscience : basic & clinical · 2026Trial
- Renal Function and Efficacy of Remote Ischemic Conditioning in Acute Moderate Ischemic Stroke: A Post Hoc Analysis of RICAMIS Trial.Brain and behavior · 2025Trial
- The correlation between serum endothelin-1 levels and aortic stiffness in patients with non-dialysis chronic kidney disease.Renal failure · 2026Article
- IGFBP2 attenuates high glucose-induced endothelial dysfunction through PI3K/Akt/eNOS pathway activation.Bioscience reports · 2026Article
- Cell-specific responses to copper stress and cuproptosis in renal fibrosis.Apoptosis : an international journal on programmed cell death · 2026Review
- Vascular Risk Factors and Late-Onset Epilepsy.JAMA neurology · 2026Article
- Chronic kidney disease as a potential risk factor for pituitary hormone dysregulation: a review of the underlying mechanisms.Molecular biology reports · 2026Review
- Vascular and Inflammatory Response Patterns Across Fixed-Sequence Handgrip Exercise Conditions in Hemodialysis Patients: An Exploratory Clinical Study with Complementary Experimental Findings.Life (Basel, Switzerland) · 2026Article
- Vascular aging as a driver of organ dysfunction and systemic aging.Nature cardiovascular research · 2026Review
- MetaboHealth and Metabolic Vulnerability Index as Risk Factors for Cardio-Renal-Metabolic Multimorbidity: A Large-Scale Prospective Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Association between tooth loss and kidney function: indirect roles of oxidative stress and systemic inflammation in NHANES 2001-2020.The Saudi dental journal · 2026Article
- Association Between Chronic Kidney Disease and Incident Ménière's Disease Using 16 Years of Nationwide Longitudinal Data.Journal of clinical medicine · 2026Article
- Article
- Multi-Omics Analysis of PBMCs Revealed Distinct Biological Differences Between Hemodialysis and Peritoneal Dialysis.International journal of molecular sciences · 2026Article
- Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.Kidney international reports · 2026Review
- Review
- Lipid Disorders in Patients with Renal Failure: Role in Cardiovascular Events and Progression of Chronic Kidney Disease.Life (Basel, Switzerland) · 2026Review
- Association of multimorbidity burden with outcomes after percutaneous coronary intervention: a retrospective cohort study.BMC cardiovascular disorders · 2026Observational
- Article
- Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial.ESC heart failure · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chronic kidney disease (CKD) is a progressive, multisystemic disorder that augments the risks of cardiovascular (CV) morbidity and mortality as kidney function declines. The endothelium plays a key role in modulating vascular tone, integrity, and homeostasis by producing and releasing a variety of endothelium-derived relaxing factors, including nitric oxide (NO). Endothelial dysfunction is a salient pathogenic mechanism underlying the development and progression of CKD and is characterized by reduced production of vasodilators and increased production of vasoconstrictors (e.g., endothelin-1). Factors such as the uremic milieu, inflammation, and oxidative stress are putative contributors of endothelial dysfunction and reduced NO bioavailability that ultimately impact functional and structural integrity of the vasculature. Because endothelial dysfunction is an independent predictor of CV morbidity and mortality in patients with CKD, several clinical studies have examined disease-related changes in endothelium-dependent vasodilation across the arterial tree. This review will focus on the clinical evidence regarding CKD-associated endothelial dysfunction involving both the micro- and macrovasculature, briefly discussing underlying physiological mechanisms, and summarizing available and emerging pharmacotherapies along with a brief summary of exercise training as a lifestyle intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.